For over sixty years, psychiatric treatment for depression and psychosis has been shaped by the serotonin and dopamine hypotheses. Despite the widespread use of antidepressants and antipsychotics, the global prevalence of these conditions has surged since the 1980s. In this groundbreaking book, the author explores the limitations of traditional treatments and presents a compelling case for reevaluating the management of chronic mental illnesses like schizophrenia.

Drawing on emerging research, the book introduces the Aryl Hydrocarbon Receptor (AhR) model as an alternative to the dopamine hypothesis. By examining the role of AhR in regulating brain and gut barriers, and its connection to severe mental illness, the author suggests innovative therapeutic strategies that go beyond dopamine blockers. These include novel approaches such as AhR antagonists, recombinant IL-22, and biophysical treatments like phototherapy and transcranial magnetic stimulation.

This book is a must-read for anyone seeking to understand the evolving science behind mental health treatment and the path toward more effective and sustainable recovery for patients with depression and psychosis.